{"id":702376,"date":"2026-01-30T10:07:26","date_gmt":"2026-01-30T15:07:26","guid":{"rendered":"https:\/\/www.kff.org\/?p=702376"},"modified":"2026-01-30T10:07:29","modified_gmt":"2026-01-30T15:07:29","slug":"recent-trends-in-glp-1-use-and-spending-in-medicare","status":"publish","type":"post","link":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/","title":{"rendered":"Recent Trends in GLP-1 Use and Spending in Medicare"},"content":{"rendered":"<div\n\tclass=\"wp-block-kff-shared-content--standard-layout wp-block-kff-shared-content\">\n\t\n\n<section class=\"wp-block-kff-shared-content-main\">\n\t\t\t<div class=\"post-header\">\n\t\t\t\t\t\n\t<h1 class=\"post-header__title\">Recent Trends in GLP-1 Use and Spending in Medicare<\/h1>\n\n\t\n\t\t\t<div class=\"post-header__meta\">\n\t\t\t\t\t<div>\n\t\t\t\t<span class=\"post-header__meta-label\">\n\t\t\t\tAuthor:\t\t\t\t<\/span>\n\t\t\t\t<a href=\"https:\/\/www.kff.org\/person\/juliette-cubanski\/\">Juliette Cubanski<\/a> \t\t\t<\/div>\n\t\t\t\t<div>\n\t\t\t<span class=\"post-header__meta-label\">Published:<\/span>\n\t\t\t<date>Jan 30, 2026<\/date>\n\t\t<\/div>\n\t\t<\/div>\n\t\n\t<div class=\"post-header__social-sharing\">\n\t\t<button class=\"post-header__social-sharing__button print\">\n\t\t\t<svg width=\"16\" height=\"17\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n\t\t\t\t<path d=\"M4.348 2.5v3.391H2.783A.787.787 0 0 0 2 6.674v4.696c0 .429.353.782.783.782h1.565V14.5h7.304v-2.348h1.565c.43 0 .783-.353.783-.782V6.674a.787.787 0 0 0-.783-.783h-1.565V2.5H4.348Zm.522.522h6.26v2.87H4.87v-2.87ZM2.783 6.413h1.782a.26.26 0 0 0 .085 0h6.697a.26.26 0 0 0 .086 0h1.784c.148 0 .261.114.261.26v4.697c0 .147-.113.26-.26.26h-1.566V9.283H4.348v2.347H2.783a.257.257 0 0 1-.261-.26V6.674c0-.147.113-.261.26-.261Zm9.39.783a.522.522 0 1 0 0 1.043.522.522 0 0 0 0-1.043ZM4.87 9.804h6.26v2.043a.264.264 0 0 0 0 .086v2.045H4.87v-2.043a.261.261 0 0 0 0-.085V9.804Zm1.043.783a.262.262 0 0 0-.265.26.26.26 0 0 0 .265.262h4.174a.26.26 0 1 0 0-.522H5.913Zm0 1.043a.26.26 0 1 0 0 .522h3.13a.26.26 0 1 0 0-.522h-3.13Zm0 1.044a.26.26 0 1 0 0 .522h4.174a.262.262 0 0 0 .264-.261.26.26 0 0 0-.264-.261H5.913Z\" fill=\"#004B88\" stroke=\"#004B88\" stroke-width=\".5\"\/>\n\t\t\t<\/svg>\n\n\t\t\tPrint\t\t<\/button>\n\t\t<a href=\"mailto:?subject=Recent%20Trends%20in%20GLP-1%20Use%20and%20Spending%20in%20Medicare&#038;body=https%3A%2F%2Fwww.kff.org%2Fmedicare%2Frecent-trends-in-glp-1-use-and-spending-in-medicare%2F\" class=\"post-header__social-sharing__button\">\n\t\t\t<svg width=\"16\" height=\"17\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n\t\t\t\t<path d=\"M2.333 4.25h-.25v9.14h12.5V4.25H2.333Zm1.083 1.693-.353-.2V5.23h10.54v.513l-.353.2L8.333 8.73 3.416 5.943Zm-.353 6.467V6.884l.107.06 5.04 2.857.123.07.123-.07 5.04-2.857.107-.06v5.526H3.063Z\" fill=\"#004B88\" stroke=\"#004B88\" stroke-width=\".5\"\/>\n\t\t\t<\/svg>\n\n\t\t\tEmail\t\t<\/a>\n\t\t<button class=\"post-header__social-sharing__button copy\">\n\t\t\t<svg width=\"16\" height=\"17\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n\t\t\t\t<path d=\"M11.533 2.9c-.615 0-1.23.235-1.697.702L8.502 4.936a2.4 2.4 0 0 0-.575 2.46l.958-.958a1.32 1.32 0 0 1 .371-.748l1.334-1.333a1.331 1.331 0 0 1 1.886 0c.52.52.52 1.365 0 1.885l-1.334 1.333c-.21.21-.474.331-.748.372l-.958.958a2.393 2.393 0 0 0 2.46-.576l1.334-1.333a2.402 2.402 0 0 0 0-3.394 2.393 2.393 0 0 0-1.697-.702Zm-1.61 3.46a.533.533 0 0 0-.367.162l-3.2 3.2a.533.533 0 1 0 .754.754l3.2-3.2a.534.534 0 0 0-.387-.915ZM6.586 7.973a2.388 2.388 0 0 0-1.816.697l-1.334 1.333a2.403 2.403 0 0 0 0 3.394 2.393 2.393 0 0 0 1.697.702c.614 0 1.229-.234 1.697-.702l1.333-1.334a2.4 2.4 0 0 0 .576-2.46l-.959.958a1.32 1.32 0 0 1-.37.749l-1.334 1.333a1.334 1.334 0 0 1-1.886-1.885l1.334-1.334c.21-.21.474-.331.748-.372l.958-.957c-.21-.07-.426-.11-.644-.122Z\" fill=\"#004B88\"\/>\n\t\t\t<\/svg>\n\n\t\t\t<span>Copy Link<\/span>\n\t\t<\/button>\n\t\t\t<\/div>\n\t<\/div>\n\t\t\t\n\n<p class=\"wp-block-paragraph\">Ahead of the Trump administration\u2019s planned expansion of Medicare coverage for GLP-1s to treat obesity through <a href=\"https:\/\/www.cms.gov\/priorities\/innovation\/innovation-models\/balance\">temporary models<\/a> and the availability of <a href=\"https:\/\/www.cms.gov\/files\/document\/fact-sheet-negotiated-prices-ipay-2027.pdf\">Medicare\u2019s negotiated price for certain GLP-1 products<\/a> beginning in 2027, new data from the Centers for Medicare &amp; Medicaid Services (CMS) shows that use and spending for these drugs under Medicare has grown substantially in recent years, reflecting their demonstrated effectiveness at treating type 2 diabetes and other conditions. Medicare currently covers GLP-1s for type 2 diabetes, cardiovascular disease, and sleep apnea, but coverage for weight loss drugs is <a href=\"https:\/\/www.ssa.gov\/OP_Home\/ssact\/title18\/1860D-02.htm#:~:text=Exclusions.%E2%80%94,and%20Drug%20Administration.\">prohibited by law<\/a>, even as GLP-1s have proved to be highly effective for this purpose (and even cost-effective, according to a <a href=\"https:\/\/icer.org\/pressreleases\/institute-for-clinical-and-economic-review-publishes-final-evidence-report-on-treatments-for-obesity\/\">recent analysis<\/a>).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">To address this gap in coverage for GLP-1s to treat obesity, CMS is launching a model called <a href=\"https:\/\/www.cms.gov\/priorities\/innovation\/innovation-models\/balance\">BALANCE<\/a> (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) under which CMS will negotiate pricing and coverage rules for GLP-1s, with the aim of expanding access to these medications and lifestyle interventions to support weight loss. The model, beginning in 2026 for Medicaid and 2027 for Medicare, is voluntary for drug manufacturers, state Medicaid programs, and Medicare Part D plans.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This analysis examines CMS\u2019s Medicare Part D claims data from <a href=\"https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicare-part-d-spending-by-drug\">2019<\/a> to <a href=\"https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicare-quarterly-part-d-spending-by-drug\">2024<\/a> to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for GLP-1s. Expansion of coverage under Medicare of GLP-1s to treat obesity under the BALANCE model is likely to increase utilization above current levels, as Medicare begins to meet the demand for obesity drugs among beneficiaries who have been unable to access or afford these medications to date. At the same time, the availability of Medicare\u2019s lower negotiated price for certain GLP-1 products under the Medicare Drug Price Negotiation Program (semaglutide beginning in 2027 and dulaglutide beginning in 2028) could mitigate the increase in Medicare spending that could come about from ongoing and expanded use of these medications.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-heading-3-font-size\" id=\"h-ozempic-was-used-by-two-million-medicare-part-d-enrollees-in-2024-up-from-fewer-than-150-000-in-2019\">Ozempic Was Used by Two Million Medicare Part D Enrollees in 2024, Up from Fewer Than 150,000 in 2019<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Semaglutide, the GLP-1 drug branded as Ozempic, Rybelsus, and Wegovy, was the most used GLP-1 in 2024. Two million Part D enrollees took Ozempic, which was <a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&amp;varApplNo=209637\">approved by the FDA in 2017<\/a> to treat type 2 diabetes, up from fewer than 150,000 in 2019 (Figure 1). Nearly 1 million Part D enrollees took Mounjaro, <a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&amp;ApplNo=215866\">approved in 2022<\/a> for type 2 diabetes, up from 54,000 in 2022. This increase reflects a pattern of growing use of newer GLP-1s, such as Ozempic and Mounjaro, while use of older products, such as Byetta (approved in 2005), Victoza (approved in 2010), and Trulicity (approved in 2014), has declined. While most GLP-1 drugs are currently available as injections, the introduction of new oral formulations, which could be easier for patients to take, could result in additional shifts in utilization among GLP-1s.<\/p>\n\n\n\n<div class=\"datawrapper-embed block--datawrapper-embed \">\n\t\t\t\t\t<div style=\"min-height: px;\">\n\t\t\t<script\n\t\t\t\ttype=\"text\/javascript\"\n\t\t\t\tdefer\n\t\t\t\tsrc=\"https:\/\/datawrapper.dwcdn.net\/8DAQ8\/embed.js?v=14\"\n\t\t\t>\n\t\t\t<\/script>\n\t\t<\/div>\n\t\t\t<img\n\t\t\tclass=\"datawrapper-embed__print-img\"\n\t\t\tsrc=\"https:\/\/datawrapper.dwcdn.net\/8DAQ8\/full.png\"\n\t\t\talt=\"The Number of Medicare Part D Enrollees Using Ozempic Has Increased Dramatically in Recent Years, Even as Medicare Coverage of GLP-1s for Obesity Remains Prohibited Under Current Law\"\n\t\t\/>\n<\/div>\n\n\n\n\n<h2 class=\"wp-block-heading has-heading-3-font-size\" id=\"h-medicare-part-d-gross-spending-on-glp-1s-increased-five-fold-between-2019-and-2024-but-estimated-rebates-of-around-50-mean-that-net-spending-is-much-lower\">Medicare Part D Gross Spending on GLP-1s Increased Five-Fold Between 2019 and 2024, But Estimated Rebates of Around 50% Mean That Net Spending is Much Lower<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Gross Medicare Part D spending on GLP-1s in 2024 (not accounting for rebates) totaled $27.5 billion, a five-fold increase from 2019, reflecting an expansion in use of GLP-1s with more recent FDA approvals for type 2 diabetes. (FDA approvals of Wegovy for cardiovascular disease and Zepbound for sleep apnea occurred in 2024 and therefore these uses are likely not reflected in Part D data through 2024.) More than half of gross spending in 2024 was on semaglutide products (Ozempic, 47%; Rybelsus, 7%; Wegovy, 1%) and nearly one fourth (23%) was for Mounjaro. Gross spending overstates the true cost of these products to the Medicare program, however. According to estimates from MedPAC, negotiated rebates for diabetic therapy were <a href=\"https:\/\/www.medpac.gov\/wp-content\/uploads\/2025\/07\/July2025_MedPAC_DataBook_Sec10_SEC-1.pdf#page=33\">equal to or greater than 50% in 2023<\/a>. Assuming rebates of 50% across all GLP-1 products in 2024 would mean net spending of around $14 billion in 2024.<\/p>\n\n\n\n<div class=\"datawrapper-embed block--datawrapper-embed \">\n\t\t\t\t\t<div style=\"min-height: px;\">\n\t\t\t<script\n\t\t\t\ttype=\"text\/javascript\"\n\t\t\t\tdefer\n\t\t\t\tsrc=\"https:\/\/datawrapper.dwcdn.net\/fFFK5\/embed.js?v=14\"\n\t\t\t>\n\t\t\t<\/script>\n\t\t<\/div>\n\t\t\t<img\n\t\t\tclass=\"datawrapper-embed__print-img\"\n\t\t\tsrc=\"https:\/\/datawrapper.dwcdn.net\/fFFK5\/full.png\"\n\t\t\talt=\"Medicare Part D Gross Spending on GLP-1s Increased Five-Fold Between 2019 and 2024, But Estimated Rebates of ~50% Mean That Net Spending is Much Lower\"\n\t\t\/>\n<\/div>\n\n\n\n\n<h2 class=\"wp-block-heading has-heading-3-font-size\" id=\"h-claims-for-glp-1s-increased-four-fold-between-2019-and-2024\">Claims for GLP-1s Increased Four-Fold Between 2019 and 2024<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In accordance with an increase in both the number of Medicare Part D enrollees using GLP-1s and spending on these products, the number of claims for GLP-1s increased four-fold between 2019 and 2024, from 4.8 million to 21.8 million, with claims doubling between 2022 and 2024 alone. More than 10 million claims for Ozempic were submitted in 2024, up from 524,000 in 2019 (an 82% average annual growth rate) and another 5.1 million for Mounjaro, up from 122,000 in 2022 (average annual growth of 549%).<\/p>\n\n\n\n<div class=\"datawrapper-embed block--datawrapper-embed \">\n\t\t\t\t\t<div style=\"min-height: px;\">\n\t\t\t<script\n\t\t\t\ttype=\"text\/javascript\"\n\t\t\t\tdefer\n\t\t\t\tsrc=\"https:\/\/datawrapper.dwcdn.net\/RP8ck\/embed.js?v=14\"\n\t\t\t>\n\t\t\t<\/script>\n\t\t<\/div>\n\t\t\t<img\n\t\t\tclass=\"datawrapper-embed__print-img\"\n\t\t\tsrc=\"https:\/\/datawrapper.dwcdn.net\/RP8ck\/full.png\"\n\t\t\talt=\"The Number of GLP-1 Claims in Medicare Part D Increased Four-Fold Between 2019 and 2024, With Claims Doubling Between 2022 and 2024 Alone\"\n\t\t\/>\n<\/div>\n\n\n\n\n<div class=\"is-style-blue-box wp-block-tenup-callout\">\n\t\n\t\t\t<div class=\"wp-block-tenup-callout__content\">\n\t\t\t\n\n<p class=\"wp-block-paragraph\">This work was supported in part by Arnold Ventures. KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities.<\/p>\n\n\t\t<\/div>\n\t\n\t<\/div>\n\n\t<div class=\"post-footer\">\n\t<div class=\"post-footer__title\">More On<\/div>\n\t<div class=\"post-footer__links\">\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.kff.org\/topic\/medicare\/\">\n\t\t\t\tMedicare\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.kff.org\/tag\/medicare-part-d\/\">\n\t\t\t\tMedicare Part D\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.kff.org\/tag\/obesity\/\">\n\t\t\t\tObesity\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.kff.org\/tag\/prescription-drugs\/\">\n\t\t\t\tPrescription Drugs\t\t\t<\/a>\n\t\t\t<\/div>\n<\/div>\n\t<\/section>\n\n\n<section class=\"wp-block-kff-shared-content-sidebar\">\n\t\t\t\n\t\t\n<div class=\"wp-block-kff-shared-related-content--green wp-block-kff-shared-related-content\">\n\t<h2 class=\"wp-block-kff-shared-related-content__heading\">Related Content<\/h2>\n\t<div>\n\t\t\t<div class=\"wp-block-kff-shared-related-content__card\">\n\t\t\t<a href=\"https:\/\/www.kff.org\/medicaid\/medicaid-coverage-of-and-spending-on-glp-1s\/\" class=\"wp-block-kff-shared-related-content__link\">\n\t\t\t\t<h3 class=\"wp-block-kff-shared-related-content__card-title\">\n\t\t\t\t\tMedicaid Coverage of and Spending on GLP-1s\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t<div class=\"wp-block-kff-shared-related-content__card\">\n\t\t\t<a href=\"https:\/\/www.kff.org\/health-costs\/medicare-spending-on-ozempic-and-other-glp-1s-is-skyrocketing\/\" class=\"wp-block-kff-shared-related-content__link\">\n\t\t\t\t<h3 class=\"wp-block-kff-shared-related-content__card-title\">\n\t\t\t\t\tMedicare Spending on Ozempic and Other GLP-1s Is Skyrocketing\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t<div class=\"wp-block-kff-shared-related-content__card\">\n\t\t\t<a href=\"https:\/\/www.kff.org\/medicare\/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation\/\" class=\"wp-block-kff-shared-related-content__link\">\n\t\t\t\t<h3 class=\"wp-block-kff-shared-related-content__card-title\">\n\t\t\t\t\tThe IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\t\t\t<\/section>\n\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ahead of the Trump administration\u2019s planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicare\u2019s negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMS\u2019s Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.<\/p>\n","protected":false},"author":48717755,"featured_media":702493,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"authors":[{"type":"foundation","id":67181,"name":"","_id":"5e936068-e3d7-4911-badf-bdb18abb7de3"}],"exhibits":[],"jetpack_post_was_ever_published":false,"ep_exclude_from_search":false,"_classifai_error":"","_classifai_text_to_speech_error":"","hide_from_search":false,"show_featured_image":false,"subheading":"","tag":"","search_keywords":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"shortlink":"","footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[69737],"tags":[38834,5705,69739],"content-types":[579145483],"series":[],"program":[155109811],"partner":[],"class_list":["post-702376","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicare","tag-medicare-part-d","tag-obesity","tag-prescription-drugs","content-types-issue-brief","program-program-on-medicare-policy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.9 (Yoast SEO v25.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Recent Trends in GLP-1 Use and Spending in Medicare | KFF<\/title>\n<meta name=\"description\" content=\"Ahead of the Trump administration\u2019s planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicare\u2019s negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMS\u2019s Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recent Trends in GLP-1 Use and Spending in Medicare | KFF\" \/>\n<meta property=\"og:description\" content=\"Ahead of the Trump administration\u2019s planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicare\u2019s negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMS\u2019s Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/\" \/>\n<meta property=\"og:site_name\" content=\"KFF\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-30T15:07:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-30T15:07:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/The-Number-of-GLP-1-Claims-in-Medicare-Part-D-Increased-Four-Fold-Between-2019-and-2024-With-Claims-Doubling-Between-2022-and-2024-Alone_FI.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"kffjuliettec\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"kffjuliettec\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/\"},\"author\":[{\"@id\":\"https:\/\/www.kff.org\/#\/schema\/person\/41b7d5d5453c18736d78ffb01d45ee51\"}],\"headline\":\"Recent Trends in GLP-1 Use and Spending in Medicare\",\"datePublished\":\"2026-01-30T15:07:26+00:00\",\"dateModified\":\"2026-01-30T15:07:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/\"},\"wordCount\":734,\"publisher\":{\"@id\":\"https:\/\/www.kff.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/The-Number-of-GLP-1-Claims-in-Medicare-Part-D-Increased-Four-Fold-Between-2019-and-2024-With-Claims-Doubling-Between-2022-and-2024-Alone_FI.png\",\"keywords\":[\"Medicare Part D\",\"Obesity\",\"Prescription Drugs\"],\"articleSection\":[\"Medicare\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/\",\"url\":\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/\",\"name\":\"Recent Trends in GLP-1 Use and Spending in Medicare | KFF\",\"isPartOf\":{\"@id\":\"https:\/\/www.kff.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/The-Number-of-GLP-1-Claims-in-Medicare-Part-D-Increased-Four-Fold-Between-2019-and-2024-With-Claims-Doubling-Between-2022-and-2024-Alone_FI.png\",\"datePublished\":\"2026-01-30T15:07:26+00:00\",\"dateModified\":\"2026-01-30T15:07:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/#primaryimage\",\"url\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/The-Number-of-GLP-1-Claims-in-Medicare-Part-D-Increased-Four-Fold-Between-2019-and-2024-With-Claims-Doubling-Between-2022-and-2024-Alone_FI.png\",\"contentUrl\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/The-Number-of-GLP-1-Claims-in-Medicare-Part-D-Increased-Four-Fold-Between-2019-and-2024-With-Claims-Doubling-Between-2022-and-2024-Alone_FI.png\",\"width\":1600,\"height\":900},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.kff.org\/#website\",\"url\":\"https:\/\/www.kff.org\/\",\"name\":\"KFF - The independent source for health policy research, polling, and news\",\"description\":\"The independent source for health policy research, polling, and news\",\"publisher\":{\"@id\":\"https:\/\/www.kff.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.kff.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.kff.org\/#organization\",\"name\":\"KFF\",\"url\":\"https:\/\/www.kff.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.kff.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/04\/KFF_Black.png\",\"contentUrl\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/04\/KFF_Black.png\",\"width\":3186,\"height\":1296,\"caption\":\"KFF\"},\"image\":{\"@id\":\"https:\/\/www.kff.org\/#\/schema\/logo\/image\/\"}},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.kff.org\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Recent Trends in GLP-1 Use and Spending in Medicare\",\"item\":\"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Recent Trends in GLP-1 Use and Spending in Medicare\"}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.kff.org\/#\/schema\/person\/41b7d5d5453c18736d78ffb01d45ee51\",\"name\":\"Juliette Cubanski\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.kff.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2013\/04\/Cubanski-Juliette.jpg?w=300\",\"contentUrl\":\"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2013\/04\/Cubanski-Juliette.jpg?w=300\",\"caption\":\"Juliette Cubanski\"},\"url\":\"https:\/\/www.kff.org\/person\/juliette-cubanski\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Recent Trends in GLP-1 Use and Spending in Medicare | KFF","description":"Ahead of the Trump administration\u2019s planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicare\u2019s negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMS\u2019s Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/","og_locale":"en_US","og_type":"article","og_title":"Recent Trends in GLP-1 Use and Spending in Medicare | KFF","og_description":"Ahead of the Trump administration\u2019s planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicare\u2019s negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMS\u2019s Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.","og_url":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/","og_site_name":"KFF","article_published_time":"2026-01-30T15:07:26+00:00","article_modified_time":"2026-01-30T15:07:29+00:00","og_image":[{"width":1600,"height":900,"url":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/The-Number-of-GLP-1-Claims-in-Medicare-Part-D-Increased-Four-Fold-Between-2019-and-2024-With-Claims-Doubling-Between-2022-and-2024-Alone_FI.png","type":"image\/png"}],"author":"kffjuliettec","twitter_card":"summary_large_image","twitter_misc":{"Written by":"kffjuliettec","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/#article","isPartOf":{"@id":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/"},"author":[{"@id":"https:\/\/www.kff.org\/#\/schema\/person\/41b7d5d5453c18736d78ffb01d45ee51"}],"headline":"Recent Trends in GLP-1 Use and Spending in Medicare","datePublished":"2026-01-30T15:07:26+00:00","dateModified":"2026-01-30T15:07:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/"},"wordCount":734,"publisher":{"@id":"https:\/\/www.kff.org\/#organization"},"image":{"@id":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/#primaryimage"},"thumbnailUrl":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/The-Number-of-GLP-1-Claims-in-Medicare-Part-D-Increased-Four-Fold-Between-2019-and-2024-With-Claims-Doubling-Between-2022-and-2024-Alone_FI.png","keywords":["Medicare Part D","Obesity","Prescription Drugs"],"articleSection":["Medicare"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/","url":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/","name":"Recent Trends in GLP-1 Use and Spending in Medicare | KFF","isPartOf":{"@id":"https:\/\/www.kff.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/#primaryimage"},"image":{"@id":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/#primaryimage"},"thumbnailUrl":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/The-Number-of-GLP-1-Claims-in-Medicare-Part-D-Increased-Four-Fold-Between-2019-and-2024-With-Claims-Doubling-Between-2022-and-2024-Alone_FI.png","datePublished":"2026-01-30T15:07:26+00:00","dateModified":"2026-01-30T15:07:29+00:00","breadcrumb":{"@id":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/#primaryimage","url":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/The-Number-of-GLP-1-Claims-in-Medicare-Part-D-Increased-Four-Fold-Between-2019-and-2024-With-Claims-Doubling-Between-2022-and-2024-Alone_FI.png","contentUrl":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/The-Number-of-GLP-1-Claims-in-Medicare-Part-D-Increased-Four-Fold-Between-2019-and-2024-With-Claims-Doubling-Between-2022-and-2024-Alone_FI.png","width":1600,"height":900},{"@type":"WebSite","@id":"https:\/\/www.kff.org\/#website","url":"https:\/\/www.kff.org\/","name":"KFF - The independent source for health policy research, polling, and news","description":"The independent source for health policy research, polling, and news","publisher":{"@id":"https:\/\/www.kff.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kff.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.kff.org\/#organization","name":"KFF","url":"https:\/\/www.kff.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kff.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/04\/KFF_Black.png","contentUrl":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2025\/04\/KFF_Black.png","width":3186,"height":1296,"caption":"KFF"},"image":{"@id":"https:\/\/www.kff.org\/#\/schema\/logo\/image\/"}},{"@type":"BreadcrumbList","@id":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kff.org"},{"@type":"ListItem","position":2,"name":"Recent Trends in GLP-1 Use and Spending in Medicare","item":"https:\/\/www.kff.org\/medicare\/recent-trends-in-glp-1-use-and-spending-in-medicare\/"},{"@type":"ListItem","position":3,"name":"Recent Trends in GLP-1 Use and Spending in Medicare"}]},{"@type":"Person","@id":"https:\/\/www.kff.org\/#\/schema\/person\/41b7d5d5453c18736d78ffb01d45ee51","name":"Juliette Cubanski","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kff.org\/#\/schema\/person\/image\/","url":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2013\/04\/Cubanski-Juliette.jpg?w=300","contentUrl":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2013\/04\/Cubanski-Juliette.jpg?w=300","caption":"Juliette Cubanski"},"url":"https:\/\/www.kff.org\/person\/juliette-cubanski\/"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/The-Number-of-GLP-1-Claims-in-Medicare-Part-D-Increased-Four-Fold-Between-2019-and-2024-With-Claims-Doubling-Between-2022-and-2024-Alone_FI.png","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pgulFb-2WIE","jetpack-related-posts":[{"id":616539,"url":"https:\/\/www.kff.org\/health-costs\/medicare-spending-on-ozempic-and-other-glp-1s-is-skyrocketing\/","url_meta":{"origin":702376,"position":0},"title":"Medicare Spending on Ozempic and Other GLP-1s Is Skyrocketing","author":"kffjuliettec","date":"Mar 22, 2024","format":false,"excerpt":"This policy watch analyzes the latest data on Medicare Part D spending on GLP-1 drugs, initially approved to treat diabetes but in high demand as treatments for obesity, and shows how spending on these drugs has increased substantially in recent years.","rel":"","context":"In &quot;Health Costs&quot;","block_context":{"text":"Health Costs","link":"https:\/\/www.kff.org\/topic\/health-costs\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/03\/FEATURE-updated-Medicare-ozempic.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/03\/FEATURE-updated-Medicare-ozempic.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/03\/FEATURE-updated-Medicare-ozempic.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/03\/FEATURE-updated-Medicare-ozempic.png?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":644390,"url":"https:\/\/www.kff.org\/medicaid\/medicaid-coverage-of-and-spending-on-glp-1s\/","url_meta":{"origin":702376,"position":1},"title":"Medicaid Coverage of and Spending on GLP-1s","author":"kffcarenec","date":"Jan 16, 2026","format":false,"excerpt":"This brief discusses the current landscape of Medicaid GLP-1 coverage and examines recent trends in Medicaid prescriptions and gross spending on GLP-1s.","rel":"","context":"In &quot;Medicaid&quot;","block_context":{"text":"Medicaid","link":"https:\/\/www.kff.org\/topic\/medicaid\/"},"img":{"alt_text":"Medicaid Programs in 13 States Covered GLP-1s for Obesity as of January 2026","src":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/GLP-1-map-no-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/GLP-1-map-no-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/GLP-1-map-no-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2026\/01\/GLP-1-map-no-logo.png?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":616585,"url":"https:\/\/www.kff.org\/health-costs\/gross-medicare-spending-on-ozempic-and-other-glp-1s-is-already-skyrocketing-even-though-medicare-cannot-cover-the-drugs-for-weight-loss\/","url_meta":{"origin":702376,"position":2},"title":"Gross Medicare Spending on Ozempic and Other GLP-1s Is Already Skyrocketing \u2013 Even Though Medicare Cannot Cover The Drugs for Weight Loss","author":"kffrainl","date":"Mar 23, 2024","format":false,"excerpt":"A KFF analysis shows that gross total Medicare spending on Ozempic and other similar drugs has increased dramatically in recent years \u2013 even though Medicare is explicitly prohibited by law from covering the drugs for obesity. That\u2019s because Medicare now covers the drugs, known as GLP-1s, for other medically accepted\u2026","rel":"","context":"In &quot;Health Costs&quot;","block_context":{"text":"Health Costs","link":"https:\/\/www.kff.org\/topic\/health-costs\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2023\/10\/kff-news-release-4-2.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2023\/10\/kff-news-release-4-2.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2023\/10\/kff-news-release-4-2.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2023\/10\/kff-news-release-4-2.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":647583,"url":"https:\/\/www.kff.org\/medicare\/proposed-coverage-of-anti-obesity-drugs-in-medicare-and-medicaid-would-expand-access-to-millions-of-people-with-obesity\/","url_meta":{"origin":702376,"position":3},"title":"Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity","author":"kfflizw","date":"Nov 26, 2024","format":false,"excerpt":"This policy watch examines the implications of new proposed regulations that would allow Medicare and require Medicaid to cover drugs used to treat obesity, including a relatively new class of highly effective but costly drugs known as GLP-1s.","rel":"","context":"In &quot;Health Costs&quot;","block_context":{"text":"Health Costs","link":"https:\/\/www.kff.org\/topic\/health-costs\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/11\/JIAS-ViewpointThe-ground-has-shifted-under-PEPFAR-what-does-that-mean-for-its-future-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/11\/JIAS-ViewpointThe-ground-has-shifted-under-PEPFAR-what-does-that-mean-for-its-future-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/11\/JIAS-ViewpointThe-ground-has-shifted-under-PEPFAR-what-does-that-mean-for-its-future-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/11\/JIAS-ViewpointThe-ground-has-shifted-under-PEPFAR-what-does-that-mean-for-its-future-1.png?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":619035,"url":"https:\/\/www.kff.org\/medicare\/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity\/","url_meta":{"origin":702376,"position":4},"title":"A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity","author":"kffjuliettec","date":"Apr 24, 2024","format":false,"excerpt":"The FDA recently approved a new use for Wegovy, the blockbuster anti-obesity drug, to reduce the risk of heart attacks and stroke in people with cardiovascular disease who are overweight or obese - a decision that opens the door to Medicare coverage of Wegovy, which is prohibited by law from\u2026","rel":"","context":"In &quot;Medicare&quot;","block_context":{"text":"Medicare","link":"https:\/\/www.kff.org\/topic\/medicare\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/04\/240424_Medicare-Coverage-of-Wegovy_FI.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/04\/240424_Medicare-Coverage-of-Wegovy_FI.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/04\/240424_Medicare-Coverage-of-Wegovy_FI.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/04\/240424_Medicare-Coverage-of-Wegovy_FI.png?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":620886,"url":"https:\/\/www.kff.org\/health-costs\/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs\/","url_meta":{"origin":702376,"position":5},"title":"KFF Health Tracking Poll May 2024: The Public\u2019s Use and Views of GLP-1 Drugs","author":"kffmarleyp","date":"May 10, 2024","format":false,"excerpt":"KFF\u2019s latest Health Tracking Poll examines the public\u2019s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include\u2026","rel":"","context":"In &quot;Health Costs&quot;","block_context":{"text":"Health Costs","link":"https:\/\/www.kff.org\/topic\/health-costs\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/05\/Feature_MayTracking-Poll_GLP-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/05\/Feature_MayTracking-Poll_GLP-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/05\/Feature_MayTracking-Poll_GLP-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.kff.org\/wp-content\/uploads\/sites\/7\/2024\/05\/Feature_MayTracking-Poll_GLP-1.png?resize=700%2C400&ssl=1 2x"},"classes":[]}],"primary_topic":"Medicare","publishpress_future_action":{"enabled":false,"date":"2026-02-23 06:17:03","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"KFF","distributor_original_site_url":"https:\/\/www.kff.org","push-errors":false,"_links":{"self":[{"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/posts\/702376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/users\/48717755"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/comments?post=702376"}],"version-history":[{"count":7,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/posts\/702376\/revisions"}],"predecessor-version":[{"id":702445,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/posts\/702376\/revisions\/702445"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/media\/702493"}],"wp:attachment":[{"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/media?parent=702376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/categories?post=702376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/tags?post=702376"},{"taxonomy":"content-types","embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/content-types?post=702376"},{"taxonomy":"series","embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/series?post=702376"},{"taxonomy":"program","embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/program?post=702376"},{"taxonomy":"partner","embeddable":true,"href":"https:\/\/www.kff.org\/wp-json\/wp\/v2\/partner?post=702376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}